

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

THE INCLUSION IN CHINA’S NATIONAL REIMBURSEMENT DRUG LIST OF 開坦尼® (CADONILIMAB) AND 依達方®(IVONESCIMAB)

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the most recent National Reimbursement Drug List (the “**NRDL**”) released by China’s National Healthcare Security Administration has been updated to include 開坦尼® (cadonilimab, PD-1/CTLA-4) and 依達方® (ivonescimab, PD-1/VEGF) for the first time. The most recent NRDL will become effective on January 1, 2025.

Cadonilimab is a novel global first-in-class PD-1/CTLA-4 bi-specific immuno-therapy drug independently developed by the Company. Cadonilimab has been included in the most recent NRDL for the treatment of recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy. Cadonilimab addresses a huge unmet medical need for immuno-therapy for advanced cervical cancer in China. In addition to the treatment of recurrent or metastatic cervical cancer, cadonilimab as a first-line treatment of advanced gastric cancer was approved in September 2024. The supplemental new drug application (the “**sNDA**”) of cadonilimab as a first-line treatment of advanced cervical cancer is under review. Currently, the Company is conducting more than 23 clinical trials that include cadonilimab in combination therapies. These clinical trials cover 16 indications that include gastric cancer, liver cancer, lung cancer and other types of cancer.

Ivonescimab is a novel global first-in-class PD-1/VEGF bi-specific immuno-therapy drug independently developed by the Company. Ivonescimab has been included in the most recent NRDL for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) mutations that progressed after treatment with EGFR tyrosine kinase inhibitors (TKI) in combination with pemetrexed and carboplatin. In a Phase III study, ivonescimab demonstrated a statistically significant and clinically meaningful superiority versus pembrolizumab as a first-line monotherapy for PD-L1 positive NSCLC. The sNDA of this indication is under fast-track review. Meanwhile, nearly 10 Phase III trials of ivonescimab are progressing efficiently in China and the rest of the World. The Company is conducting more than 25 clinical trials of ivonescimab covering 17 indications that include lung cancer, pancreatic cancer, breast cancer, hepatocellular carcinoma, head and neck cancer, and colorectal cancer.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive director

Hong Kong, November 28, 2024

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.